PD-1 Checkpoint Inhibitor Associated Autoimmune Encephalitis

Case Reports in Oncology

Volumn 10, Issue 2, 2017, Pages 473-478

  Schneider, Stephanie ^a   Potthast, Silke ^b   Komminoth, Paul ^c   Schwegler, Guido ^b   Böhm, Steffen ^a  

^a Oncology/Hematology ^*  (Switzerland)

^b Limmattal Hospital   (Switzerland)

^c TRIEMLI HOSPITAL   (Switzerland)

Author keywords

Adverse event; Autoimmune encephalitis; Checkpoint inhibitor; Nivolumab; Non small cell lung cancer; PD 1

Indexed keywords

ACICLOVIR; BACLOFEN; BISOPROLOL; CLORAZEPATE; CREATININE; GLUCOSE; HEMOGLOBIN; LACTIC ACID; LAMOTRIGINE; LEVETIRACETAM; LISINOPRIL; METHYLPREDNISOLONE; MIDAZOLAM; NIVOLUMAB; PROGRAMMED DEATH 1 RECEPTOR; SODIUM;

AGED; ALLERGIC ENCEPHALITIS; ARTICLE; BABINSKI REFLEX; BACTERIAL PNEUMONIA; CASE REPORT; CLINICAL ARTICLE; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; EPILEPSY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; MALE; MULTIPLE CYCLE TREATMENT; MYOCLONUS; PLEOCYTOSIS; PRIORITY JOURNAL; SEIZURE; SQUAMOUS CELL LUNG CARCINOMA; THROMBOCYTE COUNT; TUMOR REGRESSION;

EID: 85020230863     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000477162     Document Type: Article

References (9)

1. Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, Goeppner D, Hassel JC, Meier F, Tietze JK, Forschner A, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM: Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016;60:210-225.
2. Williams TJ, Benavides DR, Patrice K-A, Dalmau JO, Ribeiro de Avila AL, Le DT, Lipson EJ, Probasco JC, Mowry EM: Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 2016;73:928-933.
3. Mandel JJ, Olar A, Aldape KD, Tremont-Lukats IW: Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci 2014;344:229-231.
4. Full prescribing information OpdivoTM (nivolumab). http://www.accessdata.fda.gov/drugsatfda-docs/label/2016/125554s022lbl.pdf, Bristol-Myers Squibb Company, 2016.
5. Full prescribing information KeytrudaTM (pembrolizumab). http://www.accessdata.fda.gov/drugsatfda-docs/label/2016/125514s012lbl.pdf, Merck Sharp & Dohme Corp., 2016.
6. Full prescribing information TecentriqTM (atezolizumab). http://www.accessdata.fda.gov/drugsatfda-docs/label/2016/761041s000lbl.pdf, Genentech Inc., 2016.
7. Full prescribing information YervoyTM (ipilimumab) http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/125377s073lbl.pdf, Bristol-Myers Squibb Company, 2015.
8. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, Cortese I, Dale RC, Gelfand JM, Geschwind M, Glaser CA, Honnorat J, Haeftberger R, Iizuka T, Irani SR, Lancaster E, Leypoldt F, Pruess H, Rae-Grant A, Reindl M, Rosenfeld MR, Rostasy K, Saiz A, Venkatesan A, Vincent A, Wandinger K-P, Waters P, Dalmau J: A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016;15:391-404.
9. Cuzzubbo A, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, Lebbe C, Belin C, Ursu R, Carpentier AF: Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 2017;73:1-8.